Novartis’ trial of Entresto reveals potential beyond HFrEF treatment
Category: #health  By Pankaj Singh  Date: 2019-11-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Novartis’ trial of Entresto reveals potential beyond HFrEF treatment

Swiss pharma-company Novartis has reportedly revealed subgroup results from its global PARAGON-HF Phase III study. The trial involved a study of patients suffering from HFpEF (heart failure with preserved ejection fraction) or diastolic heart failure.

According to the analyses, Entresto shows considerably more promise than valsartan in reducing hospitalizations and fatalities from cardiovascular ailments, in certain subgroups. Greater advantage was observed in recently hospitalized HFpEF patients and female HFpEF patients.

Additionally, in a group analysis of PARADIGM-HF (HFrEF) and PARAGON-HF (HFpEF), treatment benefits were more prominent in patients with LVEF (left ventricular ejection fraction) less than 60%. Currently there is so approved treatment for HFpEF, which occurs disproportionately among women.

The new findings from the trial were revealed at the American Heart Association or AHA Scientific Session 2019. Publications of hospitalization analysis in the Journal of the American College of Cardiology and gender analysis in Circulation were also released simultaneously.

Entresto is presently an approved and vital treatment for HFrEF patients, generally involving less than or equal to 40% ejection fraction. This approval is based on its supremacy over enalapril, an ACE or angiotensin-converting enzyme. This superiority helps the drug reduce cardiovascular fatalities and hospitalizations due to heart failure, as revealed in the PARADIGM-HF trial.

Director of Noninvasive Cardiology at Brigham & Women’s Hospital, Harvard Medical School Professor and Executive Committee Co-Chair of PARAGON-HF, Scott Solomon, M.D., has apparently claimed that these new results demonstrate the benefits of Entresto in patients beyond HFrEF threshold. He further stated that these analyses would help gain a deeper understanding of HFpEF’s heterogeneous nature and unlock the potential advantage of Entresto for patients with unmet treatment needs.

PARAGON-HF Phase III complete results were presented at the 2019 ESC Congress. The study revealed a 13% relative decrease in the number of cardiovascular hospitalizations and deaths, narrowly missing statistical significance.
 

Source Credit: https://www.novartis.com/news/media-releases/novartis-paragon-hf-analyses-suggest-entresto-benefit-beyond-hfref



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...